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A safe method for rapidly achieving plasma 
concentration plateaus 
The classical procedure of administering a loading dose as a bolus intravenous iniection 
and at the same time starting an infusion at a constant rate could be dangerous or lead 
to toxicity with certain drugs. Under such conditions the ratio of the initial plasma 
concentration (C~) to the steady-state plasma concentration (C?) is often large. The 
higher the ratio of drug in tissues/drug in plasma (i.e., the more "two compartment" 
the drug is) the higher will be the C~/Crlq ratio. A method is proposed in which 
initially a constant-rate infuSion at the rate of Q 1 is given over T hours (0.25 to 3 
hr); then the rate is abruptly changed to a lower rate Q 2' which is maintained as long 
as steady state is desired. A simple relationship is given that shows what the ratio of 
Q/Q2 must be to attain steady state most rapidly and to minimize the ratio 
cM1x /C"?, where cM1x is the maximum plasma concentration attained at time 
T, iust as the infusion at the higher rate ceases. A simple linear graph is given 
that allows rapid determination of the needed ratio Q / Q 2' Variables needed for a 
given drug to use the method are plasma clearance and plasma half-life. 
John G. Wagner, Ph.D. Ann Arbor, Mich. 
The College of Pharmacy and Upiohn Center for Clinical Pharmacology, The University 
of Michigan 
The accumulation of a drug in the hu-
man body during a constant-rate intra-
venous infusion was first treated mathe-
matically by Widmark and Tandberg," 
based on the one-compartment open model. 
Based on this analysis, the loading dose 
(units of mass) needed to rapidly attain 
the steady state is equal to the infusion rate 
Supported in part by United States Public Health 
Service Grant No. 5-Pll-GMI5559. 
Received for publication Jan. 24, 1974. 
Accepted for publication May 8, 1974. 
Reprint requests to: Dr. John G. Wagner, Upjohn 
Center for Clinical Pharmacology, the University of Michi-
gan, Ann Arbor, Mich. 48105. 
(units of mass/time) divided by the elimi-
nation rate constant (units of l/time). The 
elimination rate constant is equal to the 
natural logarithm of 2 (namely, 0.693) 
divided by the half-life of the drug. The 
theory, based on this one-compartment 
analysis, indicates that if one administers 
this loading dose by rapid intravenous in-
jection and, at the same time, starts a con-
stant-rate infusion, a steady state will be 
"instantaneously" established and the plas-
ma concentration of drug would be the 
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Schema I. 
It is desirable to rapidly attain steady 
state in many pharmacokinetic studies, 
such as renal clearance studies, as well as 
in the therapy of certain diseases where the 
site action of the drug is in the central 
(plasma) compartment. Using the preced-
ing conditions, many clinicians appear to 
be unaware that the initial plasma concen-
tration at time zero (just after injection 
of the loading dose) can be very much 
higher than the final steady-state plasma 
concentration, since, frequently, the first 
blood sample is not taken until an hour 
or more after injection of the loading dose 
and the start of the intravenous infusion, 
while the drug obeys the two-compart-
ment rather than the one-compartment 
open model. 
Most drugs really do not obey the one-
compartment model, but rather the two-
compartment open model, depicted in 
Schema 1. In this model k12 and k21 are first-
order distribution rate constants and kel is 
the first-order elimination rate constant. 
The plasma concentration is taken as rep-
resentative of the concentration, C l , in 
compartment No. 1 (also called the "cen-
tral" compartment) at time t after admin-
istration. When a drug obeys this model 
the apparent elimination rate constant, /3, 
obtained from terminal plasma concentra-
tion data, is a complex function of kl2 , k21' 
and kel; the half-life of elimination, ob-
tained from plasma concentration data, is 
t\2 = 0.693//3. 
Clinical Pharmacology 
and Therapeutics 
During the past decade the parameters 
k12, k2h keh and VI of the model shown in 
Schema I have been published for many 
drugs. This report shows how a given set 
of parameters for a given subject or animal 
and for a given drug may be used to cal-
culate two successive infusion rates that 
provide rapid attainment of steady-state 
plasma levels and the maximum plasma con-
centration attained at the end of the initial 
infusion at the faster rate. Although most 
useful for pharmacokinetic studies, the 
method may find some application in thera-
py of certain diseases also. 
Experimental and results 
Conceptual infusion at one rate only. If 
a constant-rate infusion is given without a 
loading dose it takes a long time to ap-
proach steady state. This is indicated by 
Fig. 1, which shows the time-course for 
the first 10 hours for theophylline, based 
on the average values of the parameters 
of 3 subjects published by Mitenko and 
Ogilvie.3 The simulation is based on a 
steady-state plasma concentration of 10 
p.g/ml. In this case it would require 18.77 
hours (equivalent to 4.26 half-life periods 
of theophylline) to reach 95% of the 
steady-state value (i.e., 9.5p.g/ml) and 
9.94 hours (equivalent to 2.25 half-life 
periods) to reach 80% of the steady-state 
value (i.e., 8.0p.g/ml). For drugs with 
half-lives that are greater than about 0.5 hr., 
the Single-infusion method is not very prac-
tical. 
Infusion plus loading dose. For the 
model shown in Schema I, the relative 
values of the loading dose (R) and the in-
fusion rate (Q) are critical in determining 
the time-course of plasma concentrations. 
Boyes and associates l recommended that 
the relationship should be R = Q/kel. 
Mitenko and Ogilvie4 recommended that 
the relationship should be R = Q//3. The 
simulations shown in Fig. 2 are typical of 
the. results that would be achieved with 
theophylline with these recommendations. 
When R = Q/kel then at t = 0, C~ = 10 
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Fig. 1. Time-course of simulated theophylIine plasma concentrations with infusion rate of 
0.656 mg/kg/hr. Curve is based on Equations 1 and 2 of the Appendix, using average 
values of the parameters of three subjects, namely'" = 6.36 hr,-l (3 = 0.157 hr,-l k" = 
2.16 hr,-l V, = 0.142 mllkg, published by Mitenko and Ogilvie. 3 Calculation was made 
for C"~ = 10 flg/m!. 
drops, reaches a minimum, then slowly rises 
and approaches the equilibrium concen-
tration of 10 Itg/ml again. When R = Q//3, 
then at t = 0, C~ = 29.4 /tg/ml and the 
plasma concentration drops rapidly and 
within about 1 hour is essentially equal to 
the steady-state concentration of 10 /tg/ml. 
The ratio of the initial concentration (G) 
to the equilibrium concentration (C';'l) is 
equal to k,,[//3. The inverse ratio, /3/k.J, in-
dicates how "two compartment" a particu-
lar drug is. The smaller this ratio the great-
er the amount of drug in compartment No. 
2 compared with the amount in compart-
ment No. 1 at any time (Schema I). The 
influence of this ratio on the ratio of C~ I' 
C"? is shown in Fig. 3. Kruger-Thiemer,z 
recommended administering the loading 
dose, then a continuous infusion, the rate 
of which decreases exponentially to the 
proper steady-state rate, but this is more 
difficult than the new method proposed. 
Two consecutive infusions. A new meth-
od is described below in which an initial 
constant-rate infusion is given at a rate Ql 
over T hours. At the end of T hours the 
infusion rate is abruptly changed to a 
lower rate Q" which is maintained as long 
as a steady-state plasma concentration is 
desired. 
A critical ratio of Ql/Q" has been deter-
mined (Equation 8, Appendix), which 
provides the most rapid attainment of the 
steady state. The steps required to apply 
the method are indicated below (see also 
Table I): 
1. Choose the equilibrium state plasma 
level desired (i.e., choose C'~I). 
2. Calculate the final infusion rate as fol-
lows: 
Q~ = Plasma clearance x C~'l. 
3. Choose the time T over which to ad-
minister the initial infusion at the rate Ql' 
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Fig. 2. Time-course of simulated theophylline plasma concentrations, based on same parameters 
as in Fig. l. Curve A is for recommendation of Mitenko and Ogilvie4 where R = Qlf3. 
Curve B is for recommendation of Boyes and associates 1 where R = Q/k". In both case~ 
Q = 0.656 mg/kg/hr and C·1q = 10 JLglml. 
This often can be 0.25 hr (15 min), but 
with some toxic drugs should be as long 
as 3 or 4 hours. Fig. 6 and Equation 18 
aid in the choice of T. 
4. Calculate the ratio of the half-life of 
the drug (ty,) to the chosen time T (i.e., 
ty,/T) . 
5. Use the graph in Fig. 4 for this value 
of ty,/T to nnd the ratio Ql/QZ' 
6. Since you know Q2 you can now cal-
culate Ql since Ql = (Qt!Qz) (Qz). 
The above procedure is accurate as long 
at ty,/T is equal to or greater than 6.93. 
Whenever the ratio ty,/T is less than 6.93 
then Ql should be calculated by means of 
Equation 7 (Appendix). 
Fig. 5 illustrates the results to be 
achieved with this method with theophyl-
line and a comparison is made of the re-
sults that would be obtained by the method 
of Mitenko and Ogilvie.4 For this simula-
tion the average parameter values of theo-
phylline, given by Mitenko and Ogilvie/ 
for 7 asthmatic patients were used. These 
values were a = 5.99 hr\ f3 = 0.162 hrl, 
k.! = 0.312 hr-\ and VI = 0.277 l/kg. 
From these one can calculate k12 = 2.73 
hri and kZl = 3.11 hri. The simulation is 
based on choosing C"~l = 10 ,ug/ml and 
T = 0.5 hr. The steps for this example, cor-
responding to steps 1 to 6 above, are as 
follows: 
1. C'~l = 10 ,ug/ml. 
2. Qz = V lke!Ce~ (0.277) (0.312) 
(10) = 0.864 mg/kg/hr. 
3. T = 0.5 hr. 
4. ty, = 0.693/ f3 = 0.693/0.162 = 4.28 hr 
and ty,/T = 4.28/0.5 = 8.56. 
5. Using Fig. 4 one finds QrlQz 12.8 
corresponding to ty,/T = 8.56. 
6. Hence, Ql = (12.8) (0.864) 11.1 
mg/kg/hr. 
It should be noted that the curves shown 
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Fig. 3. Relationship between the ratio of the initial plasma concentration to the equilibrium 
plasma concentration (C~/Ce?) and the ratio ,8/k,.,. 
Table I. Data used to prepare the approximate plot of Q,/Q2 vs tv./T shown in 
Fig. 4 
Col. 4 
Col. 1 Col. 2 Col. 3 Q, = lI(l-e-PT) Col. 5 
tv,/T ,8T 1I/3T Q, 0.5 + 1.443 (t'hIT)" 
90 0.0077 129.9 130.4 130.4 
32 0.02166 46.18 46.68 46.68 
30 0.0231 43.25 43.79 43.79 
15 0.0462 21.65 22.15 22.15 
10 0.0693 14.43 14.93 14.93 
6.93 0.1000 10.00 10.508 10.50 
5 0.1386 7.216 7.727 7.715 
3 0.23105 4.328 4.847 4.829 
2.079 0.3333 3.000 3.528 3.500 
0.693 1.0000 1.000 1.582 1.500 
0.50 1.386 0.7215 1.3335 1.222 
















°For the first six values of Cols. 1 and 4, least-squares linear regression gave the equation 01/02 = 0.50 + 1.443 (t'h/T) 
with a correlation coefficient equal to 1.00000. The estimated values from this equation are shown in Col. 5. The error of 
the value in Col. 5 from the actual value in Col. 4 is shown in Col. 6. For values of to/liT less than 6.93 (shown in the 





















HALF-LIFE OF DRUG = ~ 
RATIO OF INITIAL INFUSION TIME T 
Fig. 4. Convenient way to estimate the ratio of the initial infusion rate to the final infusion rate 
( Q,/Q,) from the ratio of the half-life of the drug to the duration of the initial infusion 
(t%/T). The line is based on the equation: Q,/Q, = 0.50 + 1.443 ty,/T and its source is ex-
plained in Table I. 
method3 are very similar to real plasma 
concentration, time curves of theophylline 
published by these authors, except here 
CelQ = 10 fLg/ml, whereas in their article 
Ce~ = 5fLg/ml. 
Discussion 
If we let C~AX be the maximum plasma 
concentration at time T just when the in-
fusion rates are changed in the proposed 
method (peak in Fig. 5 at 0.5 hr), then in 
this simulation cMtX = 12.9 fLg/ml, cor-
responding to C~ = 19.3 fLg/ml with the 
Ogilvie-Mitenko method. However, if T 
had been made longer (lor 2 hr) then 
CM~X would have been much smaller. This 
is the advantage of the proposed method. 
One can set the ratio of CM~X /C~Q to any 
desired value by adjusting the time T of 
the initial infusion. Once the final infusion 
is started, the time required to reach the 
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Fig. 5. Comparison of results to be achieved with proposed method (curve B) compared 
with results achieved with method of Mitenko and Ogilvie. 4 Parameters used were the averages 
for 7 asthmatic patients published by Mitenko and Ogilvie," namely a = 5.99 hr,-l f3 = 
0.162 hr,-l k,., = 0.312 hr,-l and V, = 0.277 IIkg. 
only on the value of e-<>t as in the Mitenko-
Ogilvie' method. Since 0' is usually quite 
large, then e-<>t approaches zero rapidly and 
the fall from CM~X to C'~l is rapid, as Fig. 5 
illustrates. 
In the Mitenko-Ogilvie' method, the 
ratio of C~/C"~l is equal to 1<.'1/,8. When a 
drug nearly obeys the one-compartment 
open model then ,8~ 1<..1 and C~/C";I ~ 1, 
but most drugs really obey the two-com-
partment open model and frequently 1<.'1/,8 
ranges from about 1.6 to 5. Hence C~/C'~l 
ranges from 1.6 to 5. Such high initial 
plasma concentrations can lead to toxicity, 
particularly with drugs with a narrow range 
between the toxic and therapeutic doses 
and plasma levels. I suggest that the pro-
posed consecutive infusion method is a 
much safer procedure. 
Harvard infusion pumps have different 
settings and with this type of pump it is 
easy to give an initial infusion at one rate 
and abruptly change to a lower rate simply 
by dialing to a new setting. If a drop ap-
paratus is used, one could determine the 
drop rate to provide the two rates Ql and 
Q2 and predetermine the clamp settings 
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Fig. 6. Plots of the ratio CM~X/CP,q vs tv.,/T for various values of a/{3 and {3/k,.,. The plots 
were obtained by use of Equation 18. 
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Constant rate infusion only at one rate. If a single infusion is given at the rate Q (units 
of mass/time) without a loading dose, then the concentration in the central compartment 
(equivalent to the plasma concentration) is given by Equation 1, 
Volume 16 
Number 4 




and a and f3 are defined by Wagner5 and many other authors. 
Two consecutive infusions. In this method an initial infusion is given at the rate Q, over 
T hours (Le., in the interval 0 ~ t ~ T). At time T the infusion rate is abruptly changed 
to the lower rate Q, = V,keJCe~ (i.e., for t ~ T). 
The concentration during the interval 0 ~ t ~ T will be given by Equations 1 and 2 
where Q, replaces Q in Equation 2. 






q + {(k21-a) (Q~-aA~) - ak21A~} e-,,(t-T) 
a(a-f3)V, 
{ (k,,-f3) (Q2-f3A~) - f3 kuA~} e-j3(t-l') f3( a-f3 )V, 
AT _ Q, {Ql (k2l-a)} _ T {Ql (ku-f3)} -"1' 1--+ e"- e ... k" a( a-(3) f3( a-(3) 




For C, to be always greater than or equal to C e1q during the second infusion requires that 
the coefficient of the third term of Equation 3 (Le., the coefficient of the e-j3(t-T) term) be 
equal to zero. Equating the numerator of this term to zero gives Equation 6, 
f3k21A~ - (k21-f3) (Q,-f3A~) = o. (6) 
Substituting from Equations 4 and 5 into Equation 6 and simplifying gives Equation 7, 
(7) 
Hence the concentration C, during the second infusion will always be greater than or 
equal to ce1Q . when the ratio of the infusion rates is given by 
(8) 
If a single bolus intravenous injection of a drug is administered, then the plasma concen-
tration, time curve can usually be fitted to Equation 9, 
(9) 
The plasma clearance is the ratio of the dose (D) divided by the total area under the 
concentration, time curve as indicated by Equation 10, 
D(LV.) 
V1ke1 = ABo 
-+-
a f3 
The final infusion rate, Q" is then calculated by Equation 11, 
Q2 = V,k'lCe1q = (Plasma clearance) (Ce~). 
(10) 
(11 ) 
Once Ce1q is chosen, one calculates Q2 with Equation 11. One then chooses some con-
venient time T for the first infusion and calculates the initial infusion rate Q, with Equation 7. 
Simplified method to calculate the ratio of infusion rates, QJQ,. The expansion of e-X is 
given by Equation 12, 
699 
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x2 X 3 
e-x = 1 - X + 2 - 6" + .•.• 
When x ~ 0.1 then 
e-X = 1 - x. 
Substituting /3T for x in Equation 13 gives after rearrangement 
1 - e-/3T = /3T. 
Substituting from Equation 14 and for /3 into Equation 8 gives: 







Relationship between proposed method and method of Mitenko and Ogilvie. Substituting 
from Equation 14 into Equation 8 gives 
Q/Q2 = I//3T. (16) 
Rearrangement of Equation 16 gives 
( 17) 
Since Q, T is equal to the mass of drug administered as the initial infusion over the 
time zero to T hours, this is analogous to the Mitenko and Ogilvie loading dose R. The rela-
tionship necessary to produce the Mitenko and Ogilvie result is R = Q//3. Hence the simi-
larity between the two methods is obvious. 
Estimation of CM~X and guidelines to choice of the time T. As indicated formerly, in 
application of the proposed method the maximum plasma concentration, CM~X, is reached 
at time T corresponding to the end of the infusion at the rate Q,. By letting /3 = 0.693/t." 
and r = al/3 and using Equations 1 and 8, one can derive Equation 18, 
C~AX = 1 [1 _ (kel//3)-I)~O'G93 T/t'h _(r_(ke'//3))~O'693 T/tV,]. (18) 
Ciq -0.693 T/tv, r-l r-l 
l-e 
Equation 18 indicates that the ratio CM~X IC'~1 is a complex, nonlinear function of the 
ratios al/3, /3/keJ, and t\,/T. Fig. 6 shows representative data obtained with Equation 18. 
It should be noted that the ordinate scales of each of the small figures are different to 
facilitate reading the graphs. If one knows the values of al/3, /3/kel> and t\f' one can obtain 
an exact value of CM~X ICP~ for a given value of T by use of Equation 18. However, useful 
approximations may be made from the graphs in Fig. 6. For the example given in the text 
and Fig. 5, al/3 = 36.9, /3/k'J = 0.52, tv, = 4.28, and when T = 0.5, then t,/jT = 8.56. 
Using the graph in Fig. 6 for /3/k'J = 0.5 and al/3 = 40, one estimates CM~X/CP? "'" 1.3 
for tyjT = 8.6. The actual value is 1.29 rather than 1.3. In general the graphs in Fig. 6 
indicate that low ratios of CM~X IC"? are favored by (1) lower values of b/jT, (2) high 
values of the ratio al/3, and (3) high values of the ratio /3/k"J. If the drug is very "two 
compartment" (i.e., has a low value of /3/k'J), one should choose a value of T to provide 
a relatively low value of t\f/T; this is emphasized in the graph for /3/kel = 0.2 in Fig. 
6. If such a drug has a long half-life (small value of /3) the value of al/3 will usually 
in Fig. 6. If such a drug has a long half-life (small value of /3) the value of al/3 will usually 
be large, which together with the low value of b;,/T will provide a reasonably low ratio of 
CM~x/Ce~. 
